SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 6,080,000 shares, a decrease of 25.7% from the September 30th total of 8,180,000 shares. Based on an average daily volume of 593,700 shares, the short-interest ratio is presently 10.2 days.
Hedge Funds Weigh In On SELLAS Life Sciences Group
A hedge fund recently bought a new stake in SELLAS Life Sciences Group stock. Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,446 shares of the company’s stock, valued at approximately $39,000. Renaissance Technologies LLC owned approximately 0.06% of SELLAS Life Sciences Group at the end of the most recent quarter. 17.38% of the stock is owned by institutional investors.
SELLAS Life Sciences Group Price Performance
Shares of SLS traded up $0.13 during mid-day trading on Friday, reaching $1.23. 1,015,327 shares of the company’s stock traded hands, compared to its average volume of 1,096,079. The stock’s 50-day moving average is $1.25 and its two-hundred day moving average is $1.28. SELLAS Life Sciences Group has a 12 month low of $0.50 and a 12 month high of $1.72. The stock has a market cap of $71.04 million, a P/E ratio of -1.12 and a beta of 2.39.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
- Five stocks we like better than SELLAS Life Sciences Group
- What Are the U.K. Market Holidays? How to Invest and Trade
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Calculate Options Profits
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Investing in the High PE Growth Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.